Time to Treat Hypertension in Patients With Aortic Stenosis

Brian R. Lindman, MD, MSCI; Catherine M. Otto, MD

Historically, patients with aortic stenosis (AS) rarely had concurrent systemic hypertension (HTN). Now, echocardiography allows early diagnosis, calcific remodeling has replaced rheumatic heart disease as the most prevalent cause of AS in the developed world, and the population of adults with AS is older, paralleling the demographic shift in the age of our population. In combination, these trends mean that HTN is a more common comorbidity in patients with AS and is coexistent for a longer period of time before aortic valve replacement. In studies involving younger patients with AS, the prevalence of HTN is 30% to 40%, whereas in recent series involving older patients at high risk for aortic valve replacement, the prevalence of HTN is 75% or higher.

However, a growing body of literature has reported that a high percentage of patients with significant AS do take antihypertensive and vasoactive medications without evident adverse effects. Additionally, careful hemodynamic studies in patients with severe AS treated with single doses of vasodilating medications (captopril, nitroprusside, and sildenafil) have demonstrated the safety, tolerability, and, indeed, hemodynamic benefit of vasodilation in patients with severe symptomatic AS. Those studies demonstrated that the particular vasodilating medications used result in a decrease in systemic vascular resistance and pulmonary capillary wedge pressure combined with an increase in stroke volume, but no change in heart rate. Pulmonary vascular hemodynamics also improve with a decrease in pulmonary artery pressure and pulmonary vascular resistance. Treatment with sildenafil provides relatively greater effects on the pulmonary vasculature in comparison with the effect on unloading the LV, which could have additional benefits for patients with AS and pulmonary hypertension. In these studies with a variety of vasodilators, systemic blood pressure did decrease, but there were no episodes of symptomatic hypotension reported.

In this issue of Circulation, Eleid et al report an elegant invasive hemodynamic analysis of patients with significant AS to whom a vasodilator was administered. In this study, 18 symptomatic patients with systemic HTN (systolic blood pressure >140 mm Hg) and severe low-gradient AS with preserved ejection fraction (EF) (aortic valve area [AVA] ≤ 1 cm² or indexed AVA ≤ 0.6 cm²/m²; mean gradient < 40 mm Hg; and EF > 50%) were compared with 6 symptomatic patients with low-gradient severe AS and reduced EF (≤ 50%). The administration of nitroprusside had a balanced effect on the pulmonary and systemic circulations with similar decreases in pulmonary and systemic vascular resistance and pressure (≈ 35%–40%). They also observed a 40% decrease in LV end-diastolic pressure and a trend toward a 10% increase in stroke volume and cardiac index with no change in heart rate. These data extend our understanding of the response to vasodilation of patients with AS, particularly in the subgroup of patients with low-gradient AS with a preserved EF.

Of note, the patients with preserved EF included in this study had a very elevated systemic blood pressure with an average aortic systolic pressure of 176 mm Hg and mean aortic pressure of 115 mm Hg. In future studies, it would be of interest to compare the hemodynamics in patients with chronically elevated ambulatory blood pressures versus patients with an acute elevation in blood pressure attributable to holding cardiac/antihypertensive medications on the day of the catheterization or the adrenergic stimulation from the procedure itself.

Interestingly, the administration of nitroprusside in hypertensive patients was associated with a modest but significant increase in mean transvalvular gradient from 27 to 29 mm Hg and an increase in AVA from 0.86±0.11 to 1.02±0.16 cm².
Somewhat analogous to the use of dobutamine to clarify pseudo versus truly severe AS in patients with a small AVA, low gradient, and a preserved EF, they demonstrate that nitroprusside can increase flow and provide insight into the true severity of the AS. However, cut points for determining truly severe AS based on a change in AVA and gradient with pharmacological intervention are not uniform across studies and require further investigation. Even so, the current data provide further support for the concept that systemic HTN can influence the evaluation of AS severity.

**Clinical Implications**

In managing patients with AS, it is important to recognize the high prevalence of coexistent systemic HTN, its harmful effects on LV remodeling and function, and its adverse impact on clinical outcomes. Moreover, when determining the severity of AS and making decisions about the timing of valve replacement, it is important to recognize that systemic HTN can influence the assessment of AS severity (generally causing overestimation of severity; Figure). After valve replacement is performed, there may be a greater tendency toward systemic HTN because of the increased flow from the relief of valvular afterload, which may mitigate the expected favorable effects of LV unloading with valve replacement and limit symptomatic improvement. For all these reasons, both before and after valve replacement, treatment of systemic HTN should be an important objective of medical therapy.

When managing a *symptomatic* patient with uncontrolled systemic HTN (at the time of the echocardiogram) and a small AVA, low gradient, and preserved EF, it is reasonable to redo the echocardiogram when the patient is normotensive, particularly if the measurements of AS severity are borderline between moderate and severe. It also is prudent to reassess symptoms once the patient is consistently normotensive. When managing an *asymptomatic* patient with uncontrolled systemic HTN and a small AVA, low gradient, and preserved EF, effective HTN treatment may mitigate the deleterious effects on the LV of increased systemic vascular load and potentially delay symptom onset. Although LV outflow obstruction at the level of the valve is the sine qua non of AS, increased systemic vascular load—identified most readily as systemic HTN—is often coexistent with AS and contributes to the pressure overload, hypertrophic remodeling, and dysfunction of the LV, which underlies much of the morbidity and mortality of the disease. As such, we must remember to treat the patient (including HTN and other cardiovascular comorbidities) and not have a myopic focus on the valve alone to provide the best clinical outcomes.

**Sources of Funding**

Dr Lindman was supported by K23 HL116660 from the NIH.

**Disclosures**

None.

**References**


KEY WORDS: Editorials & aortic valve stenosis & hypertension
Time to Treat Hypertension in Patients With Aortic Stenosis
Brian R. Lindman and Catherine M. Otto

_Circulation_. 2013;128:1281-1283; originally published online August 16, 2013; doi: 10.1161/CIRCULATIONAHA.113.005275
_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/128/12/1281

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/